The pharmaceutical giant AstraZeneca has announced an increase in sales as there has been higher demand for cancer sales.
The pharmaceutical giant reported revenues of £21 billion in the first six months of 2025 and AstraZeneca is preparing to plug £37 million into their US expansion.
Oncology products for the diagnoses and treatment of cancer was 43% of AstraZeneca’s sales and pre-tax profits soared by 27% to £4.9 billion in the same period.
“Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent,” Pascal Soriot, AstraZeneca’s chief executive, said.
“This landmark investment reflects not only America’s importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca’s ambition to deliver 80 billion dollars revenue by 2030.”
